JaLCDOI 10.18926/AMO/30518
フルテキストURL fulltext.pdf
著者 Miwa, Hiroaki| Ono, Fumio| Moriyama, Minoru| Kobayashi, Tsutomu| Oka, Tetsuhide| Nakamura, Kenji| Orita, Kunzo|
抄録 <p>In 156 cases of gastric cancer, levamisole (LMS) was administered at a daily dose of 150 mg for three consecutive days every other week. The administration was started 3 days before operation. This medication was repeated for more than one month. The survival rate up to two years after surgery was studied. The survival rate was not affected in patients with Stage I and II gastric cancer, but in patients with Stage III, the difference in the survival rate between the LMS group and the control group was significantly higher than that in the control group (p less than 0.05). In patients with Stage IV, the survival rate in the LMS group was higher than that in the control group although the difference was not significant. In patients of Stage III and IV, the effect of LMS on the survival rate was highest in cases with curative resection (p less than 0.01). In cases with noncurative resection, the difference between the LMS group and the control group was greatest (24.4%) 12 months after surgery but not significant (p less than 0.5), and also in cases without resection the difference between the two groups was greatest (20.3%) 12 months after surgery but not significant (p less than 0.2).</p>
キーワード levamisole immunochemotherapy gastric cancer survival time.
Amo Type Article
発行日 1980-09
出版物タイトル Acta Medica Okayama
34巻
4号
出版者 Okayama University Medical School
開始ページ 275
終了ページ 281
ISSN 0386-300X
NCID AA00508441
資料タイプ 学術雑誌論文
言語 English
論文のバージョン publisher
査読 有り
PubMed ID 6452030
Web of Science KeyUT A1980KK16800006